Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2016 - 2025)

Collegium Pharmaceutical has reported Liabilities and Shareholders Equity over the past 10 years, most recently at $1.7 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $1.7 billion for Q4 2025, changed 0.41% from a year ago — trailing twelve months through Dec 2025 was $6.5 billion (up 18.69% YoY), and the annual figure for FY2025 was $1.7 billion, changed 0.41%.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.7 billion at Collegium Pharmaceutical, up from $1.6 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for COLL hit a ceiling of $1.7 billion in Q4 2024 and a floor of $646.1 million in Q1 2021.
  • Median Liabilities and Shareholders Equity over the past 5 years was $1.2 billion (2022), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 92.88% in 2022 and later dropped 13.22% in 2024.
  • Collegium Pharmaceutical's Liabilities and Shareholders Equity stood at $692.1 million in 2021, then surged by 69.65% to $1.2 billion in 2022, then fell by 2.63% to $1.1 billion in 2023, then soared by 45.51% to $1.7 billion in 2024, then decreased by 0.41% to $1.7 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $1.7 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.